Anti-Human CD20 – DyLight® 755

Purified Recombinant Human CD20 (>98%)

This DyLight^® 755 conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.

This DyLight^® 755 conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Clone 2H7 recognizes an epitope on human CD20.

CD20 is a 33-37 kD transmembrane-spanning phosphoprotein that facilitates optimal B-cell immune response against T-independent antigens. It can exist in a complex with MHC class I, MHC class II, CD53, CD81, and CD82. However, CD20 can also form homo-oligomers. It has been suggested that homo-oligomerization of CD20 forms calcium ion channels in the plasma membrane of B cells. CD20 can be useful in diagnosing B-cell lymphomas and leukemias, and is the target of mAbs in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. Interestingly, studies show a link between the immune system's B cells and diabetes mellitus in which anti-CD20 antibodies rendered the T cell antibodies dysfunctional and, hence, unable to cause insulin desensitivity by a B cell antibody-modulated autoimmune response.

CD20 is present on human pre B lymphocytes and on B lymphocytes, except on plasma cells, and is expressed in tandem with surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset.

Src family tyrosine kinases, MHC class I, II, CD53, CD81, CD82

1. Stashenko, P. et al. (1980) J. Immunol. 125:1678 2. Fang, D. et al. (2005) Cancer Res. 65:9328 3. Bubien, J. K. et al. (1993) J. Cell Biol. 121:1121 4. White, M. W. et al. (1991) J. Immunol. 146:846 5. Cragg, M. S. et al. (2005) Curr. Dir. Autoimmun. 8:140